PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Apr 06, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

Marietta, Ohio, April 6, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of...Read more

Mar 19, 2020

bybhenderson

dry-eye

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule. During recent testing conducted by...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.